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independent components was used (FimQAPro). Dose-maps were 
compared to treatment plans using isodoses and gamma. Absolute film 
dose values were used with no re-normalisation of any data. Isolated 
source doses were compared to TG-43 source model values. The value 
and sensitivity of gamma for brachytherapy applications was assessed 
by multivariate analysis of area/position and calculation parameters. 
Eckert & Ziegler Bebig GmbH HDR multiSource treatment unit, with 
Co-60 source, and HDRplus treatment planning system (TPS) were 
used throughout. 
Results: Figure 1 shows dose maps from 2 films positioned adjacent to 
and bisecting the cervix applicator intrauterine (IU) channel, overlaid 
on TPS isodoses. Agreement in isodoses, 75 cGy to 2000 cGy, is 
generally within 1.0 mm. A comparison of the 2 symmetric films 
confirms sufficient reproducibility. Table 1 provides example gamma 
results for the cervix and shielded vaginal applicators. The passing 
rate in brachytherapy is sensitive to the defined interest region, in the 
cervix example ranging from 95% at typical HR-CTV to 100% at a 
bladder position, for 3% (local) / 2 mm criteria, evaluated over 9 cm2 
regions. The full-region, 144 cm2, passing rate was ~ 98%. 
The validity of the TG-43 general source model for individual supplied 
HDR sources was successfully verified. Gamma passing rates > 95% at 








Conclusions: There is an absence of clinically-relevant QC for modern 
brachytherapy. We have presented a practical, robust method of 
advanced film dosimetry of treatment applicators, which is more 
closely aligned to clinical treatments than current QC. Planned and 
measured isodoses agreed closely, with high gamma passing rates. 
Film dosimetry is advocated to confirm validity of the general TG-43 
model for individual supplied sources. The use and sensitivity of 
gamma for brachytherapy must be carefully considered; we propose 
separate calculations in a number of clinically relevant regions. 
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Purpose/Objective: In permanent seed implant prostate 
brachytherapy the actual dose delivered to the patient may be less 
than that calculated by TG43-U1 due to inter-seed attenuation (ISA) 
and differences between prostate tissue composition and water. In 
this study the ISA effect is assessed using Monte Carlo (MC) simulation 
of clinical prostate treatment plans. 
Materials and Methods: Simulations of ultrasound based pre-plans and 
CT based post-plans were performed for 30 patients treated with 6711 
seeds, the mean activity used was 0.44U. MC simulation results were 
compared to TG43-U1 using DVH parameters for the prostate, urethra, 
rectum and the volume enclosed by the 100% isodose. Use of gamma 
index values to compare MC simulation results and TG43-U1 was 
investigated. Areas of the prostate where ISA caused dose to drop 
below 100% of prescription dose were analysed. Sector analysis of ISA 
effects was performed dividing the prostate into apex, mid-gland and 
base segments, with each segment divided into anterior, posterior, 
left and right quadrants. 
Results: For CT post-plans, the mean ISA effect was to reduce 
prostate D90 by 4.2Gy (3%), prostate V100 by 0.5cc (1.4%), urethra 
D10 by 11.3Gy (4.4%), rectal D2cc by 5.5Gy (4.6%) and the 100% 
isodose volume by 2.3cc. For ultrasound pre-plans the mean ISA effect 
was smaller, reducing prostate D90 by 2.2% and the 100% isodose 
volume by 1.5cc. For distance to agreement 2mm and dose difference 
3% the number of points in the prostate with gamma <=1 was 95.3% 
for CT based post-plans and 97.8% for US based pre-plans. The number 
of points with gamma <=1 correlated strongly with ISA effect on DVH 
parameters (p<0.01). Sector analysis showed that in CT post-plans the 
majority of points where ISA causes prostate dose to fall below 100% 
are near the prostate base however this is not true for ultrasound pre-
plans as these have more uniform coverage and seed spacing. 
Conclusions: ISA causes the delivered dose in prostate seed implant 
brachytherapy to be lower than the dose calculated by TG43-U1. 
Because of differences in seed positions between pre-plan and post-
plan, the effect of ISA on the post-plan could not necessarily be 
predicted from the pre-plan. For this group of patients ISA had most 
impact at the prostate base, an area which is often underdosed even 
excluded any effects of ISA.  
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Purpose/Objective: It is well-known that tissue heterogeneities and 
calcifications have significant influence on low energy brachytherapy 
such as prostate permanent I-125 implants. The aim of this work is to 
study the application of a simplified analytic algorithm that could be 
compatible with commercial Treatment Planning System (TPS) based 
on TG-43. The algorithm, based on the classic equivalent path length 
method, has been tested with Monte Carlo (MC) computations using 
Penelope2009. 
Materials and Methods: The analytical model scales the distance from 
the seed to the calculation point according to the electronic density 
of the medium relative to water. Then the dose is obtained from TG-
43 consensus data stored on a TPS but with the radial dose function 
obtained for the scaled distance keeping the anisotropy function 
unaltered. A voxelized phantom obtained from real cases has been 
used. This case was selected as a benchmark because the patient 
presented a significant proportion of calcifications inside the prostate. 
After this step a comparison between MC and the algorithm was 
performed.  
Results: The results given by the algorithm show a remarkable 
agreement with the complete Monte Carlo simulations taking into 
account the calcifications in the aforementioned real case. Several 
other realistic geometries and compositions of the calcification have 
been checked successfully. In the figure below two different imaging 
planes can be observed (black arrows in the insets). Blue lines stands 
for TG-43 based results, green lines for the algorithm, and red ones 
for MC simulations. More overdose rate times the distance squared 
and divided by air-kerma strength is given. 
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Conclusions: The presented analytical dose calculation algorithm is 
applicable for any type of heterogeneity. The high calculation speed 
of the algorithm makes it feasible for use in clinical real time- 
treatment planning and thus for improving treatment quality. 
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Purpose/Objective: To evaluate and compare the dosimetric 
parameters of intraoperative treatment plans in prostate seed 
implants performed with loose seed and stranded seed techniques.  
Materials and Methods: Permanent prostate brachytherapy with I-125 
seeds as a monotherapy for patients with low and intermediate risk 
prostate cancer was implemented at our institute in 2009, and since 
then 147 patients have been treated. The first 79 patients were 
implanted with loose seeds (seedSelect, Nucletron) and the next 68 
patients with stranded seeds (IsoSeed, Bebig). Loose seeds (LS) were 
delivered automatically with the seedSelectron system, while 
stranded seeds (SS) were placed into the prostate manually. For 
treatment planning the SPOT PRO 3.1 (Nucletron) software was used 
for all patients. The number and positions of seeds were calculated 
with an inverse dose optimization algorithm (IPSA) in the pre-implant 
plan. Then, the seeds were implanted under transrectal ultrasound 
guidance, and their real positions were updated in live planning. The 
prescribed dose was 145 Gy. Dose-volume histograms were calculated 
and volumetric parameters were used to evaluate the plans. V100 (%), 
DHI, D90 (Gy) and COIN were determined for the prostate, while Dmax 
(%), D0.1cm3 (%), D10 (%), D30 (%) for the urethra, and Dmax (%), 
D0.1cm3 (Gy), D2cm3 (Gy), D10 (%) for the rectum. Means and standard 
deviations were calculated and compared for both intervention 
groups. 
Results: On average, 54 and 47 seeds were implanted in the prostate 
with individual median seed activities of 0.49 and 0.56 mCi for LS and 
SS technique, respectively. The median needle number was 15 and 17, 
correspondingly. The mean prostate volumes were practically 
identical (33.4 vs. 33.9 cm3). The dose coverage was similar (V100: 
96% vs. 97%, D90: 167 Gy vs.169 Gy) in the two groups, and the dose 
homogeneity was identical (DHI: 0.39). The conformity of dose 
distributions was better for LS (COIN: 0.70 vs. 0.65). Regarding the 
dose to urethra all dosimetric parameters were significantly lower 
(p<0.05) for LS (Dmax: 138% vs. 154%, D0.1cm3: 126 vs. 140 %, D10: 125 
vs. 136 % and D30: 119 vs. 128 %). The rectum received less dose with 
the LS technique (Dmax: 101% vs. 112 %, D2cm3: 82 Gy vs. 97 Gy, 
D0.1cm3 :127 vs. 143 Gy, and D10: 75% vs. 86%) (p<0.05 for all). 
Conclusions: In permanent prostate seed brachytherapy the dose to 
urethra and rectum is less with LS technique compared to SS 
technique in the intraoperative plans. Moreover, the conformity of 
dose distributions is also better with LS along with the same 
homogeneity of dose distributions. Probably the more flexible loading 
pattern for LS technique results in the more favourable dose 
distributions.  
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Purpose/Objective: A survey of high dose rate (HDR) brachytherapy 
quality control (QC) procedures undertaken at radiotherapy centres in 
the United Kingdom (UK) is reported [1]. Published recommendations 
and guidance for HDR QC are also reviewed and compared to current 
UK practice. Recent changes in clinical brachytherapy techniques and 
the impact on required QC is discussed. Modern methods to determine 
optimum quality checking processes are indicated. This work is 
conducted in the context of the recent 'point/counterpoint' debate in 
Medical Physics that 'QA procedures in radiation therapy are outdated 
and negatively impact the reduction of errors' [2] and a review of the 
dosimetric accuracy in HDR [3]. 
[1] AL Palmer, M Bidmead, A Nisbet. J Contemp Brachy 2013 (in press) 
[2] HI Amols, EE Klein. Med Phys 2011; 38: 5835-5837  
[3] A Palmer, D Bradley, A Nisbet. J Contemp Brachy 2012; 4: 81-91  
Materials and Methods: All UK radiotherapy centres were asked to 
participate in a survey of their approach and practice for HDR 
brachytherapy QC. This included guidance used, frequencies and 
tolerance values for individual QC tests. A comprehensive evaluation 
of responses was conducted detailing popularity of tests, and the 
average and range values of testing and tolerance. A literature search 
was conducted on general guidance, specific QC techniques in both 
brachytherapy and teletherapy, and on risk-based systems for quality 
assurance.  
Results: Survey data was acquired from 31 UK radiotherapy centres 
and statistical analysis of responses performed. 45 possible individual 
QC tests were identified. There was general agreement on 
measurement frequency and tolerance for key QC tests, e.g. 
measurement of source position in a straight catheter, checked daily 
and with a 1.0mm tolerance in most centres. There was disagreement 
on a number of tests, e.g. the need for regular x-ray imaging of 
applicators. There was absence of tests that may be deemed 
necessary for modern brachytherapy practice, e.g. confirmation of 
planned and delivered dose distributions. There is likely a need to 
move from a device-centred to a system-centred approach, using risk-
based assessment methods to determine required QC testing, with 
emphasis on clinical processes rather than simple device operation. 
Table 1 provides sample key results from the work. 
 Conclusions: The only contemporary benchmark survey of HDR QC 
practice has been undertaken. The outcome of this work is a review of 
current practice against available recommendations, relevant recent 
changes in clinical brachytherapy techniques, and the use of modern 
quality process assessments. Recommendations for appropriate, 
optimised QC for HDR brachytherapy are made. 
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